Figure 8.
Figure 8. Adoptive transfer with #213 scFv CAR-T cells suppressed growth of mesothelioma cell line, which was enhanced by the DC vaccine. Three-day MESO-1– or MESO-4–bearing NOG mice (n = 4) were transferred with #213 scFv CAR-T cells or CEA-specific (F11-39 scFv) CAR-T cells (1 × 107 cells) followed by vaccination with DCs (1 × 105 cells) pulsed with WT1236Y or MAGE-A4143-151. (A) Tumor volumes were measured by a caliper using the formula (length × width) at the indicated time points. (B) On day 24, PBMCs and tumor tissues were harvested and subjected to FACS analysis. In another set of experiments, tumor tissues were harvested from MESO-4 bearing NOG mice (n = 3) treated as mentioned previously on day 18 and subjected to immunohistochemical analysis. Cells with respective markers were analyzed in 6 fields, and the mean ± SD are depicted (C). Error bars represent SD of the mean. *P < .05; **P < .01. A representative result from 2 independent experiments is shown.

Adoptive transfer with #213 scFv CAR-T cells suppressed growth of mesothelioma cell line, which was enhanced by the DC vaccine. Three-day MESO-1– or MESO-4–bearing NOG mice (n = 4) were transferred with #213 scFv CAR-T cells or CEA-specific (F11-39 scFv) CAR-T cells (1 × 107 cells) followed by vaccination with DCs (1 × 105 cells) pulsed with WT1236Y or MAGE-A4143-151. (A) Tumor volumes were measured by a caliper using the formula (length × width) at the indicated time points. (B) On day 24, PBMCs and tumor tissues were harvested and subjected to FACS analysis. In another set of experiments, tumor tissues were harvested from MESO-4 bearing NOG mice (n = 3) treated as mentioned previously on day 18 and subjected to immunohistochemical analysis. Cells with respective markers were analyzed in 6 fields, and the mean ± SD are depicted (C). Error bars represent SD of the mean. *P < .05; **P < .01. A representative result from 2 independent experiments is shown.

Close Modal

or Create an Account

Close Modal
Close Modal